Sign in
PVCT Stock Price, Chart, Stats & News
Provectus Biopharmaceuticals, Inc.
Save
Provectus Biopharmaceuticals, Inc. (PVCT) does not currently pay a dividend.
24.00M
Market cap
–
Current P/E
–
Forward P/E
PVCT chart
About
Health care
Sector
Biotechnology
Industry
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy.
Similar securities
Based on sector and market capitalization
Report issue